3031413-24-5
Chemical Structure
IAM1363
- CAS No.: 3031413-24-5
- Formula:C30H33N9O2
- Molecular Weight:551.66
IUPAC Name: (E)-1-(4-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one
InChIKey: ILNQLWGODADTLL-SNAWJCMRSA-N
SMILES: N(C=1C2=C(C=CN2N=CN1)C3CCN(C(/C=C/CN(C)C)=O)CC3)C4=CC(C)=C(OC5=CC=6N(C=C5)N=CN6)C=C4
Biological Activity: IAM1363 is a selective, irreversible, and blood-brain barrier-permeable HER2 inhibitor. IAM1363 targets wild-type HER2 and oncogenic HER2 mutants (including exon 20 mutations), with no off-target EGFR inhibitory activity. IAM1363 can be used to study HER2-driven solid tumors, including colorectal cancer, non-small cell lung cancer, bladder cancer, and breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IAM1363 | 99.40% | IAM1363 is a selective, irreversible, and blood-brain barrier-permeable HER2 inhibitor. IAM1363 targets wild-type HER2 and oncogenic HER2 mutants (including exon 20 mutations), with no off-target EGFR inhibitory activity. IAM1363 can be used to study HER2-driven solid tumors, including colorectal cancer, non-small cell lung cancer, bladder cancer, and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Adjei A A, et al. IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors[J]. 2024.
- [2]. Huang Z J, et al. P3. 03.29 IAM1363 Is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC[J]. Journal of Thoracic Oncology, 2025, 20(10): S441.
